The evolving pharmacotherapeutic profile of brimonidine, an 2-adrenergic agonist, after four years of continuous use

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.1, Iss.4, 2000-05, pp. : 815-834

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacotherapeutic profile of venlafaxine

By Preskorn S.H.

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 251-252

Elsevier

Access to resources Recommend Favorite

Pharmacotherapeutic Environments for Substance use Disorders

By Gardner Tracie Kosten Thomas

The American Journal of Drug and Alcohol Abuse, Vol. 33, Iss. 5, 2007-09 ,pp. : 627-629

Informa Healthcare

Access to resources Recommend Favorite

Brimonidine

By Cantor L.B. Burke J.

Expert Opinion on Investigational Drugs, Vol. 6, Iss. 8, 1997-08 ,pp. : 1063-1084

Informa Healthcare

Access to resources Recommend Favorite

Suppression of phagosome proteolysis and Matrigel migration with the α₂-adrenergic receptor agonist dexmedetomidine in murine dendritic cells

By Ueshima Hironobu Inada Takefumi Shingu Koh

Immunopharmacology and Immunotoxicology, Vol. 35, Iss. 5, 2013-10 ,pp. : 558-566

Informa Healthcare

Access to resources Recommend Favorite

Clinical Pharmacokinetics of Lofexidine, the α 2-Adrenergic Receptor Agonist, in Opiate Addicts Plasma Using a Highly Sensitive Liquid Chromatography Tandem Mass Spectrometric Analysis

By Yu Elmer Miotto Karen Akerele Evaristo O'Brien Charles Ling Walter Kleber Herbert Fischman Marian Elkashef Ahmed Herman Barbara Al-Ghananeem Abeer

The American Journal of Drug and Alcohol Abuse, Vol. 34, Iss. 5, 2008-09 ,pp. : 611-616

Informa Healthcare

Access to resources Recommend Favorite